Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]
News [2727]
Articles [201]
Editorials [1]
Conferences [136]
elearning [13]
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...
Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014
Cediranib and chemo combo improves PFS for metastatic cervical cancer
Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK
Cediranib and chemo combo improves PFS for metastatic cervical cancer ( Dr Raymond 'Paul' Symonds - University Hospital of Leicester, Leicester, UK )
28 Sep 2014
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for...
Dr Sandra Swain - Washington Cancer Institute, Washington, USA
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer ( Dr Sandra Swain - Washington Cancer Institute, Washington, USA )
28 Sep 2014
Adding cediranib to chemo improves PFS for metastatic cervical cancer
Dr Paul Symonds - University Hospital of Leicester, Leicester, UK
Adding cediranib to chemo improves PFS for metastatic cervical cancer ( Dr Paul Symonds - University Hospital of Leicester, Leicester, UK )
28 Sep 2014
New horizons in prostate cancer: The final results of the COU-302 abiraterone...
Prof Charles Ryan and Prof Gordon McVie
New horizons in prostate cancer: The final results of the COU-302 abiraterone study ( Prof Charles Ryan and Prof Gordon McVie )
28 Sep 2014
Reducing nausea and vomiting associated with cisplatin-based chemotherapy with...
Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South...
Reducing nausea and vomiting associated with cisplatin-based chemotherapy with rolapitant ( Dr Bernardo Leon Rapoport - The Medical Oncology Centre, Johannesburg, South Africa )
27 Sep 2014
The evolving treatment landscape for HER2-positive metastatic breast cancer
Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium
The evolving treatment landscape for HER2-positive metastatic breast cancer ( Dr Hatem Azim - Institut Jules Bordet, Brussels, Belgium )
18 Sep 2014
Navigating current treatment options for HER2-positive MBC: Patient journey 1
Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria
Navigating current treatment options for HER2-positive MBC: Patient journey 1 ( Dr Rupert Bartsch - Medical University of Vienna, Vienna, Austria )
18 Sep 2014
Overview of skin cancer treatments, past, present and future
Prof John Hawk - President of the World Congress on Cancers of the Skin 2014
Overview of skin cancer treatments, past, present and future ( Prof John Hawk - President of the World Congress on Cancers of the Skin 2014 )
11 Sep 2014
Advances in CLL: Expert panel Discussion
Prof Robin Foà ; Prof Clemens Wendtner; Dr Francesc Bosch; Prof Florence...
Advances in CLL: Expert panel Discussion ( Prof Robin Foà ; Prof Clemens Wendtner; Dr Francesc Bosch; Prof Florence Cymbalista )
11 Sep 2014
Emerging treatments in CLL: Expert Discussion
Prof Robin Foà and Prof Peter Hillmen
Emerging treatments in CLL: Expert Discussion ( Prof Robin Foà and Prof Peter Hillmen )
11 Sep 2014
Melanoma live: Making patient-focused therapy decisions
Prof Dirk Schadendorf; Dr Paul Nathan; Prof Georgina Long
Melanoma live: Making patient-focused therapy decisions ( Prof Dirk Schadendorf; Dr Paul Nathan; Prof Georgina Long )
1 Aug 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation